Evidence map›Paper›PMID 32566597›Full record

ArticleAnnals of translational medicine2020

Erratum to efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial.

Fengrui Xu, Yang Zhang, Zhanhui Miao, Xiaohua Zeng, Biao Wu, Li Cai, Jinping Liu, Shusen Wang, Xichun Hu, Wenbo Zheng and 3 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Fengrui XuDepartment of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, China.
Yang ZhangDepartment of Breast Surgery, Liaocheng People's Hospital, Liaocheng 252000, China.
Zhanhui MiaoDepartment of Medical Oncology, The First Affiliated Hospital of Xinxiang University, Xinxiang 453100, China.
Xiaohua ZengDepartment of Breast Surgery, Hongqing Cancer Hospital, Chongqing 400030, China.
Biao WuDepartment of General Surgery, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
Li CaiDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, China.
Jinping LiuDepartment of Breast Surgery, Sichuan Province People's Hospital, Chengdu 610072, China.
Shusen WangDepartment of Medical Oncology, Zhongshan University Cancer Center, Guangzhou 510060, China.
Xichun HuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Wenbo ZhengDepartment of Breast Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
Zhiyue ChenDepartment of Research and Development, Jiangsu Hengrui Medicine Co., Ltd., Shanghai 200120, China.
Qing YangDepartment of Research and Development, Jiangsu Hengrui Medicine Co., Ltd., Shanghai 200120, China.
Zefei JiangDepartment of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.21037/atm.2019.07.95.].

Identifiers

PMID32566597
PMCPMC7290653

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.